JCI - Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Brian J. Druker, Nicholas B. Lydon

J Clin Invest. 2000; 105(1):3–7 doi:10.1172/JCI9083

Full text | PDF

Options: View larger image (or click on image)

Figure 3

Model of STI 571 bound within the active site of the Abl kinase. (a) Overlay of ATP (red) and STI 571 (orange). Key amino acids that interact with ATP are shown. Binding mode of STI 571 shown from above (b) and from the side (c).